Yali Deng

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Michele McTigue, Brion W. Murray, Jeffrey H. Chen et al. · Proceedings of the National Academy of Sciences · 2012 · 538 citations · Full text

Acquired Resistance to Crizotinib from a Mutation in <i>CD74</i>–<i>ROS1</i>

Mark M. Awad, Ryohei Katayama, Michele McTigue et al. · New England Journal of Medicine · 2013 · 408 citations · Full text

Genome Instability, Same Resistance Mutation, Oncogenic Agent +14

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 267 citations · Full text

Inhibitory Activity, Radiation Oncology, Fusion Kinases +14

Implications for Chk1 Regulation: The 1.7 Å Crystal Structure of Human Cell Cycle Checkpoint Kinase Chk1

Ping Chen, Chun Luo, Yali Deng et al. · Cell · 2000 · 192 citations · Full text

Signal Transduction, å Crystal Structure, Cell Division +8

Dysbiosis of gut microbiota in patients with esophageal cancer

Yali Deng, Derong Tang, Pan‐Fei Hou et al. · Microbial Pathogenesis · 2020 · 105 citations

Dysbiosis, Esophageal Cancer, Gut Microbiology +5